Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study, to Assess the Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)

NCT04704063 is registered in ClinicalTrials.gov with Yuen Kah Hay as lead sponsor.

NCT NCT04704063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04704063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study, to Assess the Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)
Lead sponsor
Yuen Kah Hay
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2021
Completion date
October 1, 2023
Enrollment
170 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic steatosis, nafld